Table 2 Overall survival according to prognostic factors

From: Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Parameter n Median OS (months) Range 1-Year OS (%) 95% CI (lower–upper) P-v alue
Total population 75 10.0 0.9–55.2 39.1 6.6–12.6  
Tertiary IPI at second relapse
 0–2 46 12.6 0.9–55.2 51.3 8.8–30.8 0.0007
 >2 19 5.3 1.2–27.3 21.1 2.3–10.4  
DFI after ASCT a
 <6 months 28 5.7 1.1–55.2 21.4 3.4–7.3 0.0132b
6, <12 months 21 11.3 0.9–49.2 47.6 6.6-NA  
12 months 22 12.6 1.3–46.2 52.5 7.5–30.8  
Response to third-line therapy
 CR/CRu 22 37.7 7.3–55.2 90.5 17.4–NA <0.0001b
 PR 9 10.0 2.3–45.8 44.4 2.3–NA  
 s.d./PD 34 6.3 1.2–36.8 13.4 5.3–9.5  
Transplantation
 Yes 16 17.4 0.9–49.2 68.2 7.3–NA 0.1106
 No 57 8.0 4.8–55.2 31.2 5.8–10.6  
  1. Abbreviations: ASCT=autologous stem cell transplantation; CI=confidence interval; CRu=CR undetermined; DFI=disease-free interval; IPI=International Prognosis Index; NA=not available; OS=overall survival; s.d./PD=stable disease/progressive disease.
  2. aInterval between CORAL-scheduled ASCT and relapse.
  3. bGlobal P-value.